Trinity Biotech PLC
TRIB- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000888721
No open-market purchases or sales by Trinity Biotech PLC insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $379.5K in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Trinity Biotech PLC changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 21 | 20 | −1 |
| Shares | 7.02M | 6.58M | −439.5K (−6.3%) |
| Value | $7.50M | $6.51M | −$984.4K (−13.1%) |
New holders (2)
Institutions that held Trinity Biotech PLC at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Redwood Wealth Management Group, LLC | 16,950 | $16.8K | 0.02% |
| Group One Trading, L.P. | 16,676 | $16.5K | 0.00% |
Sold out (3)
Institutions that held Trinity Biotech PLC at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Susquehanna International Group, LLP | 11,600 | $13.0K |
| BlackRock Inc. | 992 | $1.00K |
| Rockefeller Capital Management L.P. | 944 | $1.00K |